Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function

NCT00645580

NAINTERVENTIONAL

Sha'ar Menashe Mental Health Center

15 participants

Started 2008-04 · Completed 2009-04

Status: Unknown (as of 12-23-2025)

Conditions

Schizophrenia

Interventions

DRUG: Fluvoxamine

Linked Papers (from SciSciNet-V2)

Total Papers27

Background

1

Result

0

Derived

0

Unknown

26

View on ClinicalTrials.gov

Total Citations Per Year

Brief Summary

In our study we aim to examine the effect of SSRI augmentation on negative symptoms and cognitive function in schizophrenia patients as well as to examine the effect of SSRI augmentation on the RNA and protein products in peripheral mononuclear cells (PMC). Finally, we aim to relate changes in PMC elements to changes in clinical symptoms and cognitive function. Our study hypotheses are that SSRI augmentation of anti-psychotic treatment in schizophrenia patients will improve negative symptoms as well as cognitive symptoms and that this improvement will be related to biochemical changes identifiable in PMC elements.

Sort by:

Background Papers2

A peripheral marker for schizophrenia: Increased levels of D ₃ dopamine receptor mRNA in blood lymphocytes

A peripheral marker for schizophrenia: Increased levels of D ₃ dopamine receptor mRNA in blood lymphocytes

Result Papers0

No result papers linked

Derived Papers0

No derived papers linked

Unknown Papers26

Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale

4,531 citations

A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS

3,213 citations

The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations

1,384 citations

A depression rating scale for schizophrenics

1,199 citations

Cytokines and the Brain: Implications for Clinical Psychiatry

DNA microarrays in drug discovery and development

Neural plasticity to stress and antidepressant treatment

Working Memory Deficit as a Core Neuropsychological Dysfunction in Schizophrenia

Bacterial transcript imaging by hybridization of total RNA to oligonucleotide arrays

Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants

Review of Immunological and Immunopathological Findings in Schizophrenia

Fluvoxamine improves negative symptoms in treated chronic schizophrenia: An add-on double-blind, placebo-controlled study

A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia

Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain

Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients

Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression.

Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay

Signal-transducing G proteins and antidepressant Drugs: Evidence for modulation of α subunit gene expression in rat brain

Augmentation With Fluvoxamine But Not Maprotiline Improves Negative Symptoms in Treated Schizophrenia

Antagonist-mediated down-regulation of 5-hydroxytryptamine type 2 receptor gene expression: modulation of transcription.

The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex

A Method for Analysis of Gene Expression Patterns

Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine

Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia.

Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment

The mechanism of action of antidepressants revised